MX2014001971A - Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. - Google Patents
Polimeros de poli(vinilester) para suministro de acido nucleico in vivo.Info
- Publication number
- MX2014001971A MX2014001971A MX2014001971A MX2014001971A MX2014001971A MX 2014001971 A MX2014001971 A MX 2014001971A MX 2014001971 A MX2014001971 A MX 2014001971A MX 2014001971 A MX2014001971 A MX 2014001971A MX 2014001971 A MX2014001971 A MX 2014001971A
- Authority
- MX
- Mexico
- Prior art keywords
- polymers
- poly
- vinyl ester
- nucleic acid
- acid delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/10—Esters
- C08F20/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F218/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid
- C08F218/02—Esters of monocarboxylic acids
- C08F218/04—Vinyl esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F218/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid
- C08F218/02—Esters of monocarboxylic acids
- C08F218/04—Vinyl esters
- C08F218/10—Vinyl esters of monocarboxylic acids containing three or more carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F218/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid
- C08F218/22—Esters containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
La presente invención se relaciona con polímeros de poli (viniléster) activos en membrana y composiciones para suministro dirigido de polinucleótidos de ARN de interferencia (ARNi) a células in vivo. Los polinucleótidos de ARNi se conjugan a los polímeros de poli (viniléster) y los polímeros se modifican reversiblemente para habilitar suministro dirigido in vivo. La actividad en membrana del poli (viniléster) proporciona movimiento de los polinucleótidos de ARNi desde el exterior de la célula al interior de la célula. La modificación reversible proporciona capacidad de respuesta fisiológica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161527703P | 2011-08-26 | 2011-08-26 | |
PCT/US2012/051968 WO2013032829A1 (en) | 2011-08-26 | 2012-08-23 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
US13/592,393 US8932572B2 (en) | 2011-08-26 | 2012-08-23 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014001971A true MX2014001971A (es) | 2014-03-31 |
Family
ID=47756738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001971A MX2014001971A (es) | 2011-08-26 | 2012-08-23 | Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. |
Country Status (11)
Country | Link |
---|---|
US (3) | US8932572B2 (es) |
JP (1) | JP2014531476A (es) |
KR (1) | KR20140051357A (es) |
CN (1) | CN104024328A (es) |
AU (1) | AU2012300476B2 (es) |
BR (1) | BR112014004585A2 (es) |
CA (1) | CA2842039A1 (es) |
HK (1) | HK1199736A1 (es) |
IL (1) | IL231146A0 (es) |
MX (1) | MX2014001971A (es) |
WO (1) | WO2013032829A1 (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
KR20140051357A (ko) * | 2011-08-26 | 2014-04-30 | 애로우헤드 리서치 코오포레이션 | In Vivo 핵산 전달용 폴리(비닐 에스테르) 고분자 |
EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US8796405B2 (en) * | 2012-01-18 | 2014-08-05 | Wisconsin Alumni Research Foundation | Degradable polycations derived from amino acid vinyl esters |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
MX2014001965A (es) * | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
EP2961843A2 (en) | 2013-02-28 | 2016-01-06 | Arrowhead Research Corporation | Organic compositions to treat epas1-related diseases |
KR20230025948A (ko) | 2013-03-13 | 2023-02-23 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 염증 치료용 면역-변형된 입자 |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
NZ631552A (en) | 2013-05-01 | 2017-02-24 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating hbv expression |
EP3030244B1 (en) | 2013-08-07 | 2021-04-21 | Arrowhead Pharmaceuticals, Inc. | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
CA2946003A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
EP3757215A3 (en) | 2014-05-01 | 2021-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
CN106232804B (zh) | 2014-05-01 | 2019-10-25 | Ionis制药公司 | 用于调节补体因子b表达的组合物和方法 |
AU2015252917B2 (en) | 2014-05-01 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
US9976141B2 (en) | 2015-05-29 | 2018-05-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of Hif2alpha |
KR102640776B1 (ko) | 2015-07-10 | 2024-02-23 | 아이오니스 파마수티컬즈, 인코포레이티드 | 디아실글리세롤 아실전이효소 2(dgat2) 조절제 |
EP3332007A4 (en) | 2015-08-07 | 2019-07-17 | Arrowhead Pharmaceuticals, Inc. | RNA INTERFERENCE THERAPY FOR HEPATITIS B VIRUS INFECTION |
US20180273577A1 (en) | 2015-09-24 | 2018-09-27 | Ionis Pharmaceuticals, Inc. | Modulators of kras expression |
JOP20210043A1 (ar) | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
BR112018008090A2 (pt) | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
AU2016341311B2 (en) | 2015-10-22 | 2023-11-16 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
HUE059127T2 (hu) | 2015-10-22 | 2022-10-28 | Modernatx Inc | Légúti vírusok elleni vakcinák |
CN109310751A (zh) | 2015-10-22 | 2019-02-05 | 摩登纳特斯有限公司 | 广谱流感病毒疫苗 |
EP3371201A4 (en) | 2015-11-06 | 2019-09-18 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
BR122023026882A2 (pt) | 2015-11-06 | 2024-01-23 | Ionis Pharmaceuticals, Inc | Uso de um composto oligomérico |
ES2919552T3 (es) | 2015-12-23 | 2022-07-27 | Modernatx Inc | Procedimientos de utilización de polinucleotidos codificadores de ligando ox40 |
US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
TWI783434B (zh) | 2016-03-07 | 2022-11-11 | 美商愛羅海德製藥公司 | 治療性化合物之標靶性配體 |
AU2017279512B2 (en) | 2016-06-06 | 2021-08-19 | Arrowhead Pharmaceuticals, Inc. | 5'-cyclo-phosphonate modified nucleotides |
EP3484524B1 (en) | 2016-07-15 | 2022-11-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of smn2 |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
JOP20170056B1 (ar) | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
EP3568482A4 (en) | 2017-01-10 | 2020-12-16 | Arrowhead Pharmaceuticals, Inc. | ALPHA-1 ANTITRYPSIN (AAT) RNA INTERFERENCE (RNA) AGENTS, COMPOSITIONS CONTAINING THEM, AND PROCEDURES FOR USE THEREOF |
JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
KR20200044013A (ko) | 2017-09-11 | 2020-04-28 | 애로우헤드 파마슈티컬스 인코포레이티드 | 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물 |
TN2020000038A1 (en) | 2017-09-14 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
CA3079413A1 (en) | 2017-10-17 | 2019-04-25 | Arrowhead Pharmaceuticals, Inc. | Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1 |
RU2020127049A (ru) | 2018-01-15 | 2022-02-17 | Айонис Фармасьютикалс, Инк. | Модуляторы экспрессии dnm2 |
AU2019218987A1 (en) | 2018-02-12 | 2020-07-23 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
CU20200082A7 (es) | 2018-05-09 | 2021-06-08 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la reducción de la expresión de fxi |
EP3833397A4 (en) | 2018-08-08 | 2023-06-14 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS |
TW202023573A (zh) | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
CN113507920A (zh) | 2019-02-07 | 2021-10-15 | 箭头药业股份有限公司 | 用于乙型肝炎病毒感染的RNAi剂 |
JP2022536945A (ja) | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | B型肝炎ウイルス(HBV)ワクチンおよびHBVを標的化するRNAiの組合せ |
EP3986456A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
CN115279379A (zh) | 2020-02-28 | 2022-11-01 | Ionis 制药公司 | 用于调节smn2的化合物和方法 |
MX2022011907A (es) | 2020-03-26 | 2023-01-05 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de pnpla3, composiciones farmacéuticas de estos, y métodos de uso. |
EP4211243A2 (en) | 2020-09-11 | 2023-07-19 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
EP4210759A1 (en) | 2020-09-11 | 2023-07-19 | Arrowhead Pharmaceuticals, Inc. | Lipid conjugates for the delivery of therapeutic agents |
AU2021340710A1 (en) | 2020-09-11 | 2023-04-06 | Arrowhead Pharmaceuticals, Inc. | Skeletal muscle delivery platforms and methods of use |
IL302817A (en) | 2020-11-18 | 2023-07-01 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating angiotensinogen expression |
JP2024514954A (ja) | 2021-04-23 | 2024-04-03 | ガナ バイオ, インコーポレイテッド | グリカン修飾核酸、調製方法、及び治療的使用 |
US11549112B1 (en) | 2021-06-21 | 2023-01-10 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
US11912997B2 (en) | 2022-06-15 | 2024-02-27 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0359003A (ja) * | 1989-07-27 | 1991-03-14 | Mitsubishi Kasei Corp | 酸感受性ポリマー |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
TW316266B (es) | 1993-07-30 | 1997-09-21 | Commw Scient Ind Res Org | |
US6291620B1 (en) | 1994-11-09 | 2001-09-18 | E. I. Du Pont De Nemours And Company | Polymer synthesis |
JPH0931057A (ja) * | 1995-07-21 | 1997-02-04 | Eiweiss Kk | プロリン骨格を有するビニルエーテル、その製法およびその重合体ならびに共重合体 |
DE69709110T2 (de) | 1996-07-10 | 2002-04-25 | Du Pont | Polymerisation mit "living" kennzeichen |
CN1252813A (zh) | 1997-04-23 | 2000-05-10 | 纳幕尔杜邦公司 | 大单体的合成方法 |
IL139666A0 (en) | 1997-07-21 | 2002-02-10 | Commw Scient Ind Res Org | Synthesis of dithioester chain transfer agents and use of bis (thioacyl) disulfides or dithioesters as chain transfer agents |
DK1054906T3 (da) | 1997-12-18 | 2007-03-26 | Du Pont | Polymerisationsproces med levende karakteristika og polymerer fremstillet derved |
WO2000075162A1 (en) * | 1999-06-07 | 2000-12-14 | Mirus Corporation | A compound containing a labile disulfide bond |
CN1406140A (zh) * | 2000-02-28 | 2003-03-26 | 吉倪塞思公司 | 纳米胶囊包封系统与方法 |
US8138383B2 (en) * | 2002-03-11 | 2012-03-20 | Arrowhead Madison Inc. | Membrane active heteropolymers |
US7816337B2 (en) * | 2003-02-18 | 2010-10-19 | Roche Madison Inc. | Reversible attachment of a membrane active polymer to a polynucleotide |
WO2008022309A2 (en) * | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
EP2500015A1 (en) * | 2006-12-05 | 2012-09-19 | Landec Corporation | Delivery of drugs |
EP2219697A2 (de) * | 2007-11-23 | 2010-08-25 | Technische Universität Wien | Durch polymerisation härtbare zusammensetzung zur herstellung biologisch abbaubarer, bioverträglicher, vernetzter polymere auf basis von polyvinylalkohol |
JP5911723B2 (ja) | 2008-05-13 | 2016-04-27 | ユニヴァーシティ オブ ワシントン | 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体 |
ES2540767T3 (es) | 2008-11-06 | 2015-07-13 | University Of Washington | Copolímeros multibloque |
CA2750485C (en) | 2009-01-23 | 2017-12-19 | Commonwealth Scientific And Industrial Research Organisation | Raft polymerisation |
JP6137834B2 (ja) | 2010-02-24 | 2017-05-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | siRNAの標的化送達のための組成物 |
US20110224377A1 (en) | 2010-03-11 | 2011-09-15 | Mahesh Kalyana Mahanthappa | Poly(vinyl ester) block copolymers |
US9376523B2 (en) | 2010-03-19 | 2016-06-28 | Wisconsin Alumni Research Foundation | Poly(vinyl alcohol)-poly(vinyl ester) block copolymers |
US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
KR20140051357A (ko) * | 2011-08-26 | 2014-04-30 | 애로우헤드 리서치 코오포레이션 | In Vivo 핵산 전달용 폴리(비닐 에스테르) 고분자 |
-
2012
- 2012-08-23 KR KR20147004852A patent/KR20140051357A/ko not_active Application Discontinuation
- 2012-08-23 BR BR112014004585A patent/BR112014004585A2/pt unknown
- 2012-08-23 US US13/592,393 patent/US8932572B2/en active Active
- 2012-08-23 CN CN201280041442.XA patent/CN104024328A/zh active Pending
- 2012-08-23 CA CA 2842039 patent/CA2842039A1/en not_active Abandoned
- 2012-08-23 WO PCT/US2012/051968 patent/WO2013032829A1/en active Application Filing
- 2012-08-23 JP JP2014527280A patent/JP2014531476A/ja active Pending
- 2012-08-23 AU AU2012300476A patent/AU2012300476B2/en not_active Ceased
- 2012-08-23 MX MX2014001971A patent/MX2014001971A/es unknown
-
2014
- 2014-02-25 IL IL231146A patent/IL231146A0/en unknown
- 2014-12-05 US US14/561,339 patent/US9089611B2/en not_active Expired - Fee Related
-
2015
- 2015-01-07 HK HK15100132.2A patent/HK1199736A1/xx unknown
- 2015-06-22 US US14/746,070 patent/US9474804B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8932572B2 (en) | 2015-01-13 |
US9474804B2 (en) | 2016-10-25 |
US20150110732A1 (en) | 2015-04-23 |
KR20140051357A (ko) | 2014-04-30 |
JP2014531476A (ja) | 2014-11-27 |
US20150283256A1 (en) | 2015-10-08 |
HK1199736A1 (en) | 2015-07-17 |
US9089611B2 (en) | 2015-07-28 |
CN104024328A (zh) | 2014-09-03 |
BR112014004585A2 (pt) | 2017-06-13 |
IL231146A0 (en) | 2014-04-30 |
US20130121954A1 (en) | 2013-05-16 |
AU2012300476A1 (en) | 2014-01-23 |
AU2012300476B2 (en) | 2016-03-24 |
WO2013032829A1 (en) | 2013-03-07 |
CA2842039A1 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014001971A (es) | Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. | |
MX2014001965A (es) | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. | |
EA201290602A1 (ru) | КОМПОЗИЦИИ ДЛЯ НАПРАВЛЕННОЙ ДОСТАВКИ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНК (миРНК) | |
WO2012083185A3 (en) | Peptide-based in vivo sirna delivery system | |
WO2012083046A3 (en) | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna | |
MX2016001006A (es) | Policonjugados para suministro de desencadenantes de acido ribonucleico de interferencia (arni) en celulas tumorales en vivo. | |
WO2012092373A3 (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | |
WO2011113030A3 (en) | Human cancer micro-rna expression profiles predictive of chemo-response | |
WO2012061719A3 (en) | Dna origami devices | |
AR081868A1 (es) | Vectores y secuencias de sulfamidasa humana para el tratamiento de mucopolisacaridosis | |
WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
MX356625B (es) | Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva. | |
WO2013158309A3 (en) | Non-disruptive gene targeting | |
CA2906970C (en) | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases | |
EP4269584A3 (en) | Selective antisense compounds and uses thereof | |
WO2005079532A3 (en) | Methods and compositions for enhancing risc activity in vitro and in vivo | |
WO2013096958A8 (en) | Compositions and methods for the delivery of biologically active rnas | |
NZ627373A (en) | Genes involved in noscapine production | |
WO2011116152A3 (en) | Delivery of agents using interfering nanoparticles | |
WO2014066915A3 (en) | Methods and compositions to produce ss-rnai activity with enhanced potency | |
WO2011046983A3 (en) | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro | |
WO2012006169A3 (en) | Compositions and methods for enhancement of nucleic acid delivery | |
MX340143B (es) | Composiciones de pared de célula de ácido ribonucléico bacterial y métodos para hacerlas y usarlas. | |
WO2009051659A3 (en) | Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo | |
PL390563A1 (pl) | Geosiatki komórkowe o obniżonym pełzaniu i wysokiej odporności na wpływy mikrobiologiczne oraz hydrolizę |